Stock Alert: BioSig Technologies (BSGM)
(RTTNews) - BioSig Technologies Inc.'s (BSGM) subsidiary ViralClear Pharmaceuticals Inc. is expected to start its first clinical trial of its drug candidate Merimepodib in COVID-19 patients this quarter.
The Company is awaiting FDA clearance to commence with the proposed phase II trial.
Merimepodib is shown to decrease viral production of COVID-19 coronavirus more than Gilead's experimental medicine Remdesivir at clinically meaningful drug concentrations in pre-clinical testing.
Jerome Zeldis, Executive Chair and Founder of ViralClear Pharma said, "We are now exploring whether remdesivir and merimepodib are synergistic in this in vitro model".
BSGM is currently up 15% trading at $8.28.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.